MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close.

The company will host a webcast beginning at 4:30 p.m. Eastern Time to review the financial results and provide a business update.

The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will be available in the same location within 24 hours following the call and will be accessible for approximately 90 days.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com. 

Contacts:
Investor Relations
Kate Miranda
Email: [email protected]

Media Relations
Christie Iacangelo
Email: [email protected]

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Norsk Hydro: Invitation to Hydro's second quarter results 2026
• STMicroelectronics unveils world’s first ST54M secure mobile chip with post-quantum cryptography for next-generation connected services